Novartis | NOVN - Ebitda


Novartis reported $6.48B in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Alcon AG USD 795M 478M Mar/2026
Almirall EUR 114.07M 60.37M Dec/2025
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Autolus Therapeutics Ltd USD -56.8M 13.28M Mar/2026
Bayer EUR 2.14B 2.31B Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Fresenius EUR 988M 37M Jun/2026
Fresenius Medical Care EUR 824M 250M Mar/2026
Genmab DKK 186M 291M Dec/2025
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
GRIFOLS EUR 473M 120M Jun/2026
Hikma Pharmaceutical USD 369M 84M Dec/2024
J&J USD 8.27B 1.08B Mar/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.53B 87M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Novo Nordisk DKK 37.36B 2.64B Jun/2026
Orion EUR 191.9M 61.5M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Philips EUR 910M 343M Jun/2026
Recordati EUR 256.6M 26.98M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
UCB EUR 1.6B 570M Dec/2025